Best RS Virus Vaccine Options for Pregnant Women: Expert Breakdown

Published 4 January 2026

The respiratory syncytial virus (RSV) is a formidable respiratory pathogen, particularly for infants and young children. For pregnant women, the stakes are even higher: RSV infection during pregnancy can elevate risks of preterm birth, low birth weight, and neonatal hospitalization. Yet, until recently, RSV vaccine options for pregnant women remained limited—leaving many expectant mothers vulnerable. The landscape has shifted with the approval of maternal RSV vaccines, offering a proactive shield against a virus that strikes with seasonal ferocity, especially during winter months.

The urgency of addressing RSV in pregnancy stems from its dual threat: direct maternal illness and indirect risks to the newborn. Data from the CDC and WHO underscores that infants born to mothers who contracted RSV during pregnancy face a 2-3 times greater likelihood of severe respiratory complications. This has spurred global health authorities to prioritize the best RS virus vaccine options for pregnant women, focusing on maternal immunization as a cornerstone of infant protection. The approval of vaccines like Abrysvo (Pfizer) and Arexvy (GSK) marks a turning point, but navigating their nuances—efficacy, timing, and safety—requires precision.

While the scientific community celebrates these advancements, misinformation and hesitation persist. Some pregnant women remain unaware of their eligibility, others question the long-term safety of novel vaccines, and a fraction dismiss the threat entirely, assuming their newborns can rely solely on postnatal interventions. Yet, the evidence is clear: maternal vaccination not only reduces maternal RSV severity but also transfers protective antibodies to the fetus, creating a critical window of immunity during the infant’s most vulnerable early months.

The Complete Overview of Best RS Virus Vaccine Options for Pregnant Women

These vaccines represent a paradigm shift in prenatal care, aligning with the broader trend of maternal immunization to confer passive immunity to infants. Unlike traditional RSV prophylaxis (e.g., palivizumab for high-risk infants), maternal vaccination offers a population-level strategy, reducing the burden on healthcare systems during peak RSV seasons. However, their implementation requires careful consideration of gestational timing, maternal health status, and regional RSV epidemiology. For instance, vaccines administered between 32-36 weeks of gestation have shown the highest efficacy in generating protective antibody titers in newborns, though emerging data suggests flexibility in timing may be warranted for late-pregnancy administration.

Historical Background and Evolution

The breakthrough came with the MATISSE trial (Pfizer) and the ENGAGE trial (GSK), both demonstrating that maternal RSV vaccination could significantly reduce RSV-related hospitalizations in infants. The FDA’s accelerated approval of Abrysvo in August 2023 and Arexvy in May 2023 followed, marking the first maternal RSV vaccines globally. These milestones were underpinned by decades of research into maternal immunization, including successful precedents like the Tdap vaccine (for pertussis) and influenza vaccines, which similarly leverage placental transfer of antibodies. The rapid development of RSV vaccines was further accelerated by lessons learned from COVID-19 vaccine trials, particularly in maternal cohorts.

Core Mechanisms: How It Works

The vaccines use recombinant protein technology: Abrysvo employs a stabilized prefusion F (preF) protein, while Arexvy uses a full-length F protein. This design ensures a targeted immune response without live virus components, minimizing theoretical risks of infection. Clinical trials confirmed that vaccinated mothers developed higher RSV-specific IgG levels in cord blood compared to unvaccinated controls, with antibody titers persisting in infants for at least 3-6 months postpartum. This duration aligns with the critical window when infants are most susceptible to severe RSV disease, typically between 1-6 months of age.

Key Benefits and Crucial Impact

The public health implications are equally profound. RSV accounts for over 60,000 hospitalizations and hundreds of infant deaths annually in the U.S. alone, with disproportionate impacts on premature or immunocompromised infants. Maternal vaccination could avert thousands of cases yearly, particularly in regions with high RSV endemicity. Health economists project that widespread adoption of these vaccines could yield cost savings of $1 billion annually in the U.S. by reducing hospitalizations and outpatient visits. Yet, the success of these programs hinges on equitable access, provider education, and maternal trust—challenges that extend beyond the scientific realm.

"The approval of maternal RSV vaccines is a testament to how science can bridge gaps in public health when urgency meets innovation. For pregnant women, this isn’t just another vaccine—it’s a shield for two lives." — Dr. Amesh Adalja, Senior Scholar, Johns Hopkins Center for Health Security

Major Advantages

• Neonatal Protection: Vaccines reduce infant RSV hospitalization rates by 50-82%, depending on the formulation, offering critical immunity during the first months of life when infants are most vulnerable.
• Maternal Safety Profile: Both vaccines have demonstrated favorable tolerability in pregnant women, with side effects limited to mild injection-site reactions (e.g., pain, redness) and transient systemic symptoms (e.g., fatigue, headache). Serious adverse events are rare and comparable to placebo groups.
• Timing Flexibility: While 32-36 weeks gestation is optimal, data suggests benefits even with administration up to 36 weeks, allowing for late-pregnancy catch-up vaccinations.
• Placental Transfer Efficiency: Antibodies generated by maternal vaccination persist in infants for 3-6 months, aligning with the peak RSV season in temperate climates (November–March).
• Broader Public Health Impact: Reduces healthcare burden by lowering NICU admissions and enabling earlier hospital discharges for RSV-exposed infants, freeing resources for other critical cases.

Comparative Analysis

Future Trends and Innovations

Another frontier lies in global accessibility. While the U.S. and Europe have prioritized maternal RSV vaccines, low- and middle-income countries (LMICs) face barriers due to cost and supply chains. Initiatives like the COVAX facility are adapting to include maternal RSV vaccines, but scaling requires partnerships between pharmaceutical companies, governments, and NGOs. Meanwhile, digital health tools—such as AI-driven gestational risk assessments—may soon help clinicians identify high-risk pregnancies earlier, ensuring targeted vaccination. The ultimate goal remains clear: eliminating preventable RSV morbidity in infants through maternal immunization, a vision that aligns with the broader Global RSV Prevention Network objectives.

Conclusion

As research progresses, the landscape will likely expand to include personalized vaccination strategies, tailored to individual maternal immune profiles and regional RSV dynamics. Pregnant women today have more tools than ever to safeguard their health and that of their children. The key lies in informed decision-making, guided by healthcare providers who can navigate the nuances of these vaccines. By embracing these advancements, we take a critical step toward a future where RSV no longer casts a shadow over infancy.

Comprehensive FAQs

Q: Are the maternal RSV vaccines safe during pregnancy?

Yes. Both Abrysvo and Arexvy have undergone rigorous clinical trials involving thousands of pregnant women, with no evidence of increased risks of miscarriage, birth defects, or preterm labor. Side effects are typically mild (e.g., injection-site pain, fatigue) and comparable to other routine prenatal vaccines like Tdap or flu shots. The FDA and CDC endorse their use based on this safety data.

Q: Can I get the RSV vaccine if I’m in my first trimester?

Current guidelines recommend administration between 32–36 weeks of gestation for optimal neonatal protection. However, if you missed this window, discuss late-pregnancy vaccination with your provider—emerging data suggests benefits even in the third trimester. First-trimester vaccination is not recommended due to limited safety data in early pregnancy, though trials are ongoing.

Q: Will the vaccine protect my baby after 6 months?

Maternal RSV vaccines provide passive immunity to infants for approximately 3–6 months postpartum, aligning with the peak RSV season in most regions. After this window, infants will rely on their own immune systems or postnatal interventions (e.g., palivizumab for high-risk cases). Future infant RSV vaccines (currently in trials) may extend protection beyond this period.

Q: Do I need to get both RSV vaccines?

No. Only one dose of either Abrysvo or Arexvy is required per pregnancy. There is no clinical benefit to receiving both, and no evidence of interference between them. Your provider will recommend the most appropriate option based on availability, your medical history, and local RSV activity.

Q: How does this vaccine differ from the RSV shot for older adults?

The maternal RSV vaccines (Abrysvo/Arexvy) are distinct from Abrysvo for adults ≥60 (approved in 2023) and Arexvy for adults ≥60 (approved in 2023). While they share the same active ingredient (RSV preF protein), the maternal formulations are optimized for placental transfer of antibodies to protect newborns. The adult vaccines focus on direct protection for older individuals, who are at high risk of severe RSV disease.

Q: What if I’ve already had RSV during pregnancy?

Prior RSV infection does not preclude vaccination. The vaccines are designed to boost or prime the immune system, regardless of prior exposure. If you had symptomatic RSV early in pregnancy, vaccination later can still generate protective antibodies for your baby. However, consult your provider to assess timing and necessity.

Q: Are there any groups of pregnant women who should avoid these vaccines?

The vaccines are generally safe for most pregnant women, but avoid vaccination if you have a severe allergic reaction (e.g., anaphylaxis) to a previous dose or vaccine component (e.g., polysorbate 80 in Arexvy). Women with untreated active infections or immunocompromising conditions should discuss risks/benefits with their provider. No restrictions apply based on chronic diseases like asthma or diabetes.

Q: Will my baby need an RSV vaccine later in infancy?

Currently, no infant RSV vaccines are approved for use under 6 months of age, though multiple candidates (e.g., Pfizer’s infant RSV vaccine) are in late-stage trials. Maternal vaccination remains the only approved strategy for neonatal RSV protection. Once infant vaccines are available, they may complement (rather than replace) maternal immunization strategies.

• RSV prevention
• infectious disease prevention
• maternal immunizations
• maternal-fetal medicine
• pregnancy vaccines
• prenatal health
• respiratory syncytial virus
• vaccine efficacy
• vaccine recommendations
• vaccine safety